OnKure Therapeutics financials
$2.60−5.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$63.0M | -$54.4M |
| Net income | -$59.5M | -$52.7M |
| Net margin | — | — |
| Diluted EPS | $-4.40 | $-15.28 |
| EBITDA | -$62.5M | -$53.9M |
| Operating cash flow | -$51.8M | -$51.1M |
| Free cash flow | -$51.9M | -$51.2M |
| Diluted shares | 13.5M | 3.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $59.0M | $110.8M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $62.1M | $114.9M |
| Total liabilities | $5.9M | $11.1M |
| Shareholders' equity | $56.2M | $103.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology